Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS: A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [24]
In the citing paper
“Large observational studies or head-to-head RCTs show similar rates of gastrointestinal and non-gastrointestinal major bleeding for single antiplatelet therapy (SAPT) with low-dose ASA or a P2Y 12 inhibitor (clopidogrel or ticagrelor).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Regarding CV safety, the composite of MI, stroke, CV death, CHD, and acute limb ischaemia was similar between pantoprazole and placebo, as was the rate of new-onset diabetes.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Thus, gastrointestinal mucosal bleeding appears to be due to pre-existing mucosal lesions associated with defective primary haemostasis secondary to platelet inhibition, rather than with a specific antiplatelet drug.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Combined antithrombotic drugs, while effective, increase major bleeding risk.337,338”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Research works printed but not linked: 1
- Feres F, 2013, JAMA, 310, 2510
Cited by
Items 601–700 of 1,001
Барбараш, О. Л., Komarov, A. L., Панченко, Е. П., Староверов, И. И., Shakhnovich, R. M., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-4-6-59 · Cited by 16
Multifocal atherosclerosis: focus on the prevention of ischemic events
Arutyunov, A. G., Батлук, Т. И., Bashkinov, R. A., & Trubnikova, M. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4808 · Cited by 16
Cardiovascular prevention in elderly patients.
Bonanad, C., Fernández-Olmo, R., García‐Blas, S., Alarcon, J. A., Díez‐Villanueva, P., Mansilla, C. R., García‐Pardo, H., Toledo, P., Ayesta, A., Pereira, E., et al. (2022) · PubMed Central · doi:10.11909/j.issn.1671-5411.2022.05.004 · Cited by 22
“There are 2 strategies: PEGASUS with ticagrelor and COMPASS with rivaroxaban with different populations (see table/figure).([63,64]) It should be noted that the DAPT, PEGASUS and COMPASS trials included a small percentage of patients over 75 years of age: 11%, 15% and 20%, respectively.”
MethodGender differences in efficacy and safety of antiplatelet strategies for acute coronary syndromes
Occhipinti, G., Greco, A., Angiolillo, D. J., & Capodanno, D. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2245331 · Cited by 16
Current Management of Non-ST-Segment Elevation Acute Coronary Syndrome
Díez‐Villanueva, P., Jiménez-Méndez, C., Guillén, P. L. C., Arenas‐Loriente, A., Fernández‐Herrero, I., García‐Pardo, H., & Díez‐Delhoyo, F. (2024) · Biomedicines · doi:10.3390/biomedicines12081736 · Cited by 17
Defining the optimal duration of DAPT after PCI with DES
Eisen, A., & Bhatt, D. L. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.87 · Cited by 17
The future of P2Y12 receptor antagonists
Thomas, M. R., & Storey, R. F. (2015) · Platelets · doi:10.3109/09537104.2015.1049519 · Cited by 17
Elewa, H. F., Ahmed, D., & Barnes, G. D. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1571337 · Cited by 17
Caracciolo, A., Mazzone, P., Laterra, G., Garcia-Ruiz, V., Polimeni, A., Galasso, S., Saporito, F., Carerj, S., D’Ascenzo, F., Marquis‐Gravel, G., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8112016 · Cited by 17
“The Dual Antiplatelet Therapy (DAPT) study was the first study with the adequate power to detect a difference for more rare ischemic events including stent thrombosis [41].”
BackgroundMeta-analysis of studies examining the external validity of the dual antiplatelet therapy score
Witberg, G., Zusman, O., Yahav, D., Perl, L., Assa, H. V., & Kornowski, R. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz075 · Cited by 16
Guedeney, P., Mesnier, J., Sorrentino, S., Abcha, F., Zeitouni, M., Lattuca, B., Silvain, J., Rosa, S. D., Indolfi, C., Collet, J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030680 · Cited by 16
“Various DAPT regimens, based on aspirin with more or less prolonged duration of more or less potent P2Y 12 inhibitors, have been evaluated to further reduce the ischemic residual risk, following ACS or PCI [23–25].”
Song, P. S., Park, Y. H., Oh, J. H., Song, Y. B., Choi, S., Gwon, H., Cho, D., Rha, S., Bae, J., Jeong, J., et al. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.03.053 · Cited by 17
Kuzemczak, M., Ibrahem, A., & Alkhalil, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01056-z · Cited by 16
“In contrast, patients without diabetes had a larger ARR when receiving extended dual antiplatelet therapy, despite their lower baseline risk compared with patients with diabetes [25].”
ResultYoshioka, G., Natsuaki, M., Goriki, Y., Shinzato, K., Nishihira, K., Kuriyama, N., Shimomura, M., Inoue, Y., Nishikido, T., Hongo, H., et al. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.10.043 · Cited by 16
Apostolos, A., Chlorogiannis, D., Vasilagkos, G., Katsanos, K. H., Toutouzas, K. G., Aminian, A., Alexopoulos, D. K., Davlouros, P. A., & Tsigkas, G. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.01.005 · Cited by 16
Brodie, B. R., Garg, A., Stuckey, T., Kirtane, A. J., Witzenbichler, B., Maehara, A., Weisz, G., Rinaldi, M. J., Neumann, F., Metzger, D. C., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002568 · Cited by 16
Self-citationVergallo, R., Aguirre, A. D., Abtahian, F., Minami, Y., Soeda, T., Chatzizisis, Y. S., Croce, K., & Jang, I. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-05-0412 · Cited by 16
Jones, W. S., Mi, X., Qualls, L. G., Turley, R. S., Vemulapalli, S., Peterson, E. D., Patel, M. R., & Curtis, L. H. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.002 · Cited by 16
Morino, Y., Terashita, D., Otake, H., Kikuchi, T., Fusazaki, T., Kuriyama, N., Suzuki, T., Ito, Y., Hibi, K., Tanaka, H., et al. (2018) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-017-0507-4 · Cited by 16
“Since the publication of key study findings [25], prolonged dual antiplatelet therapy remains the recommended strategy.”
BackgroundBenefit and Risk of Prolonged DAPT After Coronary Stenting in Women: Results From the DAPT Study
Berry, N. C., Kereiakes, D. J., Yeh, R. W., Steg, P. G., Cutlip, D. E., Jacobs, A. K., Abbott, J. D., Hsieh, W.-H., Massaro, J. M., Mauri, L., et al. (2018) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.117.005308 · Cited by 16
Self-citationWürtz, M., Olesen, K. K. W., Mortensen, M. B., Eikelboom, J. W., Mohammad, M. A., Erlinge, D., Kristensen, S. D., & Mæng, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab785 · Cited by 16
Serebruany, V. L. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.043 · Cited by 16
Bikdeli, B., Ross, J. S., Bukhari, S., Jeffery, M. M., Lip, G. Y. H., You, S. C., Cohen, D. J., Januzzi, J. L., & Wallach, J. D. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2664-7887 · Cited by 15
Self-citationRetractedStent thrombosis: a contemporary guide to definitions, risk factors, and management
Flowers, A., Evenhuis, B., Gabanic, B., Weiss, A., Eisenberg, S. D., Siddiqui, R., Rizwan, A. M., Riaz, I., Virk, H. U. H., Alam, M., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1622235 · Cited by 17
Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease
Parker, W. A., Gorog, D. A., Geisler, T., Vilahur, G., Sibbing, D., Rocca, B., & Storey, R. F. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa165 · Cited by 15
Levens, A. D., den Haan, M. C., Jukema, J. W., Heringa, M., van den Hout, W. B., Moes, D. J. A. R., & Swen, J. J. (2023) · Genes · doi:10.3390/genes14030578 · Cited by 17
“The observation of patients being on a prolonged DAPT regimen in our study is no anomaly; both the DAPT study [49] and the PEGASUS-TIMI trial [50] showed a significant reduction in cardiovascular ischemic events with DAPT beyond 1 year after index PCI, albeit paired with an increased risk of bleeding, as compared with…”
ResultMacrophage P2Y12 regulates iron transport and its inhibition protects against atherosclerosis
Hu, Y.-X., You, H.-M., Bai, M.-R., Yue, W.-H., Li, F., Hu, B., Chen, Y.-S., Shen, X., Wu, Y., Wang, J.-M., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.019 · Cited by 16
“P2Y12 inhibitors are widely used to prevent stent thrombosis and ischemic events after PCI in patients [52].”
Diretriz de Síndrome Coronariana Crônica – 2025
César, L. A. M., Gowdak, L. H. W., Pavanello, R., Ferreira, J. F. M., Mioto, B. M., Poppi, N. T., Mendonça, C. J. L., Beck, A. L. D. S., de Brito, A. S. X., Abizaid, A., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250619 · Cited by 32
Watanabe, H., Morimoto, T., Natsuaki, M., Furukawa, Y., Nakagawa, Y., Kadota, K., Yamaji, K., Andò, K., Shizuta, S., Shiomi, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124314 · Cited by 15
“However, the recently reported DAPT trial suggested that prolonged DAPT up to 30 months provided clinical benefits in reducing ST and MI [30].”
BackgroundSu, Y., Cheng, X., & Dong, Q. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12419 · Cited by 15
“15) for 30 months versus 12 months of DAPT [42].”
BackgroundLee, S., Hong, M., Shin, D., Kim, J., Kim, B., Ko, Y., Choi, D., Jang, Y., Kim, H.-S., Valgimigli, M., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004256 · Cited by 15
Qiu, M., Li, Y., Li, J., Xu, K., Jing, Q., Dong, S., Jin, Z., Zhao, P., Xu, B., & Han, Y. (2017) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26948 · Cited by 15
Felix, C. M., van den Berg, V. J., Hoeks, S. E., Fam, J. M., Lenzen, M. J., Boersma, E. H., Smits, P., Serruys, P. W. J. C., Onuma, Y., & van Geuns, R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197119 · Cited by 17
“In metal stents, prolongation of DAPT up to 30 months showed to reduce thrombotic events [39].”
BackgroundOptimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome
Jang, J., Shin, D., Kim, J., Hong, S., Ahn, C., Kim, B., Ko, Y., Choi, D., Hong, M., Park, K. W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207386 · Cited by 15
“[16] Moreover, a previous meta-analysis Fig 2.”
Yudi, M., Farouque, O., Andrianopoulos, N., Ajani, A. E., Brennan, A., Murphy, A. C., Lefkovits, J., Reid, C. M., Oqueli, E., Sebastian, M., et al. (2020) · Internal Medicine Journal · doi:10.1111/imj.14750 · Cited by 15
Silverio, A., Benvenga, R. M., Piscione, F., Gulizia, M. M., Meessen, J. M. T. A., Colivicchi, F., Nardi, F., Baldi, C., Galasso, G., Vecchione, C., et al. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420947633 · Cited by 15
Luca, L. D., Bonaca, M. P., & Magnani, G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1833719 · Cited by 15
Bernad, S. I., Crăciunescu, I., Sandhu, G. S., Dragomir‐Daescu, D., Tombácz, E., Vékás, L., & Turcu, R. P. (2020) · Journal of Magnetism and Magnetic Materials · doi:10.1016/j.jmmm.2020.167489 · Cited by 15
Kanenawa, K., Yamaji, K., Tashiro, H., Domei, T., Andò, K., Watanabe, H., & Kimura, T. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.120.010007 · Cited by 15
Samuelsen, P., Eggen, A. E., Steigen, T. K., Wilsgaard, T., Kristensen, A., Skogsholm, A., Holme, E., van den Heuvel, C., Nordrehaug, J. E., Bendz, B., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247358 · Cited by 17
“7% of patients were excluded before randomization, due to a GUSTO major bleeding during the initial 12 months [19].”
BackgroundHu, M., Lu, Y., Wan, S., Li, B., Gao, X., Yang, J., Xu, H., Wu, Y., Song, L., Qiao, S., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.01.003 · Cited by 15
Choi, K. H., Park, Y. H., Song, Y. B., Park, T. K., Lee, J. M., Yang, J. H., Choi, J., Choi, S., Oh, J. H., Chun, W. J., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.3203 · Cited by 15
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia
Rosa, G. M., Bianco, D., Valbusa, A., Massobrio, L., Chiarella, F., & Brunelli, C. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1244524 · Cited by 15
“Both the PEGASUS-TIMI 54 and DAPT trials documented a higher risk of ischemic events soon after protocol-mandated discontinuation of dual antiplatelet therapy in both the 12 and 30-month treatment arms [50,51].”
MethodSharma, A., Hai, O. Y., Garg, A., Vallakati, A., Lavie, C. J., & Marmur, J. D. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.04.001 · Cited by 15
Davenport, E. D., Syburra, T., Gray, G. W., Rienks, R., Bron, D., Manen, O., D’Arcy, J. L., Guettler, N. J., & Nicol, E. D. (2018) · Heart · doi:10.1136/heartjnl-2018-313055 · Cited by 18
Optimal Duration for Dual Antiplatelet Therapy After Left Main Coronary Artery Stenting
Choi, J., Kim, I., Cho, S., Kim, J., Hong, S., Shin, D., Ahn, C., Kim, B., Ko, Y., Choi, D., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0362 · Cited by 15
Percutaneous Coronary Intervention
Khera, S., Kolte, D. S., & Bhatt, D. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00016-4 · Cited by 15
Guedeney, P., & Collet, J. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1722188 · Cited by 16
Azzalini, L., Ellis, S. G., Kereiakes, D. J., Kimura, T., Gao, R., Onuma, Y., Chevalier, B., Dressler, O., Crowley, A., Zhou, Z., et al. (2021) · EuroIntervention · doi:10.4244/eij-d-21-00263 · Cited by 15
Self-citationMohanty, B. D., Mohanty, S., Hussain, Y., Padmaraju, C., Aggarwal, S., Gospin, R., & Yu, A. F. (2017) · Future Cardiology · doi:10.2217/fca-2017-0002 · Cited by 15
Balancing the Risks and Benefits of Dual Platelet Inhibition
Keaney, J. F. (2015) · New England Journal of Medicine · doi:10.1056/nejme1502137 · Cited by 15
Iqbal, J., & Serruys, P. W. J. C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.02.15 · Cited by 15
“DAPT, if tolerated, should be continued for a minimum of 12 months, although evidence for longer duration is emerging (10,11).”
BackgroundThe year in cardiology 2015: acute coronary syndromes
Montalescot, G., & Crea, F. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv686 · Cited by 15
Kedhi, E., Fabris, E., van der Ent, M., Kennedy, M., Buszman, P. E., von Birgelen, C., Cook, S., Wedel, H., & Zijlstra, F. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.02.018 · Cited by 14
Ткачева, О. Н., Vorobyeva, N. M., Kotovskaya, Y. V., Рунихина, Н. К., Strazhesko, I. D., Вадимовна, В. С., Drapkina, O. M., Komarov, A. L., Orlova, Y. A., Панченко, Е. П., et al. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2847 · Cited by 15
Bularga, A., Meah, M. N., Doudesis, D., Shah, A. S. V., Mills, N. L., Newby, D. E., & Lee, K. K. (2021) · Open Heart · doi:10.1136/openhrt-2021-001707 · Cited by 14
“13 This perhaps emphasises the importance of procedural variables, such as optimal stent deployment especially in patients with ACS when deciding on the duration of DAPT.”
Wang, W., Ma, Q., Li, D., Zhang, W., Yang, Z., Tian, W., & Huang, N. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.09.011 · Cited by 14
“In traditional clinical practice, patients using these devices may require long-term or even lifelong anticoagulation therapy [11 – 14].”
BackgroundGalea, R., Krsnik, J. P., Bini, T., Chalkou, K., Gasys, A., Brugger, N., Madhkour, R., Seiffge, D. J., Roten, L., Siontis, G. C. M., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2024.12.007 · Cited by 14
Actualización en cardiología intervencionista 2014
Hernández, F., Hernández, J. M. D. L. T., Cuevas, J. R. R., del Blanco, B. G., Martínez‐Sellés, M., & Trillo, R. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.12.010 · Cited by 14
Lemesle, G., Schurtz, G., Meurice, T., Tricot, O., Lemaire, N., Caudmont, S., Philias, A., Ketelers, R., Lamblin, N., & Bauters, C. (2016) · Cardiology · doi:10.1159/000442706 · Cited by 14
Sotomi, Y., Suzuki, S., Kobayashi, T., Hamanaka, Y., Nakatani, S., Hirata, A., Takeda, Y., Ueda, Y., Sakata, Y., & Higuchi, Y. (2019) · EuroIntervention · doi:10.4244/eij-d-18-00660 · Cited by 14
Marquis‐Gravel, G., Mehta, S. R., Valgimigli, M., Levine, G. N., Neumann, F., Granger, C. B., Costa, F., Lordkipanidzé, M., Roffi, M., Robinson, S. D., et al. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.12.013 · Cited by 14
Reid, C., AlTurki, A., Yan, A. T.-K., So, D. Y. F., Ko, D. T., Tanguay, J., Bessissow, A., Mehta, S. R., Goodman, S. G., & Huynh, T. T. (2020) · CJC Open · doi:10.1016/j.cjco.2020.02.005 · Cited by 14
Gajanana, D., Rogers, T., Weintraub, W. S., Kolm, P., Iantorno, M., Khalid, N. M., Chen, Y., Shlofmitz, E. S., Khan, J. M., Musallam, A., et al. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.02.032 · Cited by 14
Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine
Kaul, S. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.05.017 · Cited by 16
Croix, G. R. S., Lacy, S. C., Gazzhal, A., Ibrahim, M., Gjergjindreaj, M., Pérez, J., Shehadeh, M., Vedantam, K., Torres, C. A., Beohar, N., et al. (2022) · Journal of Interventional Cardiology · doi:10.1155/2022/3111840 · Cited by 16
“However, the benet of prolonged DAPT was decreased and the bleeding event rates increased when stratied by age [18].”
BackgroundLee, J. M., Jung, J.-H., Park, K. W., Shin, E., Oh, S. K., Bae, J., Rhew, J. Y., Lee, N., Kim, D., Kim, U., et al. (2015) · Trials · doi:10.1186/s13063-015-0925-5 · Cited by 14
“In the recent DAPT trial, change of prasugrel to clopidogrel at 30 months after PCI showed a mild increase of clinical events in the short- term period [31].”
MethodPrediction of Cardiac and Noncardiac Mortality After Percutaneous Coronary Intervention
Spoon, D. B., Lennon, R. J., Psaltis, P. J., Prasad, A., Holmes, D. R., Lerman, A., Rihal, C. S., Gersh, B. J., Ting, H. H., Singh, M., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002121 · Cited by 14
Self-citationYamaji, K., Natsuaki, M., Morimoto, T., Ono, K., Furukawa, Y., Nakagawa, Y., Kadota, K., Andò, K., Shirai, S., Watanabe, H., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.03.036 · Cited by 14
Park, S., Moon, J., Kwon, S. W., Suh, Y. J., Kim, T., Jang, H., Suh, J., Park, H. W., Oh, P. C., Shin, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159416 · Cited by 14
“The primary endpoint was all-cause mortality, while the secondary endpoint was composite major adverse cardiovascular and cerebrovascular event (MACCE), defined as all-cause mortality, non-fatal MI, non-fatal stroke, and ischemia-driven TLR/TVR,during the follow-up period [14,15].”
BackgroundHumbert, X., Roule, V., Chequel, M., Fédrizzi, S., Brionne, M., Lelong‐Boulouard, V., Milliez, P., & Alexandre, J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.212 · Cited by 14
Misumida, N., Kobayashi, A., Kim, S. M., Abdel‐Latif, A., & Ziada, K. M. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0410 · Cited by 14
Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events
Al-Salama, Z. T., Keating, G. M., & Keam, S. J. (2017) · Drugs · doi:10.1007/s40265-017-0844-8 · Cited by 14
“Interestingly, the PEGASUS-TIMI 54 criteria for high risk in patients with acute MI has been used to develop a risk score that accurately identifies patients at the highest risk for death and recurrent acute MI and who therefore may benefit from long-term DAPT; validation of the score in different patient cohorts is u…”
MethodInfluentialDoshi, R. P., Shah, J., Jauhar, V., Decter, D. H., Jauhar, R., & Meraj, P. (2018) · Heart & Lung · doi:10.1016/j.hrtlng.2018.02.004 · Cited by 14
Prehospital Diagnosis and Management of Acute Myocardial Infarction
Brown, A. J., Ha, F. J., Michail, M., & West, N. E. J. (2018) · Springer eBooks · doi:10.1007/978-981-13-1114-7_2 · Cited by 14
“While initially borne out in the context of reducing the ongoing and persistent risk of stent thrombosis, DAPT also reduces the risk of subsequent spontaneous MI in non-stented coronary segments and all-cause mortality [10].”
Biomarkers of platelet activation and cardiovascular risk in the DAPT trial
Berg, D. D., Yeh, R. W., Mauri, L., Morrow, D. A., Kereiakes, D. J., Cutlip, D. E., Gao, Q., Jarolím, P., Michelson, A. D., Frelinger, A. L., et al. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02221-5 · Cited by 14
Self-citationBleeding complications of triple antithrombotic therapy after percutaneous coronary interventions
Faza, N. N., Mentias, A. G., Parashar, A., Chaudhury, P., Barakat, A. F., Agarwal, S., Wayangankar, S. A., Ellis, S. G., Tuzcu, E. M., & Kapadia, S. R. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26574 · Cited by 14
“In light of more widespread use of drug-eluting stent necessitating longer period of treatment with DAPT, especially with recent studies suggesting prolongation of DAPT beyond 12 months, and the rising incidence of AF due to the aging population [14], we expect increasing use of TOAT.”
BackgroundSelection of P2Y 12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
Tantry, U. S., Navarese, E. P., Myat, A., & Gurbel, P. A. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.01.003 · Cited by 14
The Role of Direct Oral Anticoagulants in Patients With Coronary Artery Disease
Turgeon, R. D., Ackman, M. L., Babadagli, H. E., Basaraba, J. E., Chen, J. W., Omar, M. A., & Zhou, J. S. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418795889 · Cited by 14
“Moreover, extending DAPT beyond 1 year in patients with previous ACS or PCI provides minimal additional thrombotic protection and does not reduce the risk of death.(6,7) Five direct oral anticoagulants (DOACs) are now available in North America: apixaban, betrixaban, dabigatran, edoxaban, and rivaroxaban.”
BackgroundFanari, Z., Weiss, S. A., & Weintraub, W. S. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0131-6 · Cited by 14
“The debate of the effectiveness of longer versus 12 months of DAPT especially in high-risk ACS patients and the cost effectiveness of each approach may impact our choice of therapy [49].”
BackgroundOlive Oil Phenolics and Platelets—From Molecular Mechanisms to Human Studies
Katsa, M. E., & Nomikos, T. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2308255 · Cited by 19
“Similar conflicting results were obtained when dual antiplatelet therapy with aspirin plus purinergic receptor, P2Y12 inhibitors was studied [25,26].”
ResultAbbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk
Roffi, M., Landi, A., Heg, D., Frigoli, E., Chalkou, K., Chevalier, B., Ijsselmuiden, A. J. J., Kastberg, R., Komiyama, N., Morice, M., et al. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.08.030 · Cited by 13
Giustino, G., & Dangas, G. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.08.005 · Cited by 13
Immediate and 1-year follow-up with the novel nanosurface modified COBRA PzF stent
Maillard, L., Tavildari, A., Barra, N., Billé, J., Joly, P., Peycher, P., Silvestri, M., & Vochelet, F. (2017) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2017.04.010 · Cited by 13
Sachdeva, A., Hung, Y., Solomon, M. D., & McNulty, E. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.06.066 · Cited by 13
Nakanishi, N., Kaikita, K., Ishii, M., Kuyama, N., Tabata, N., Ito, M., Yamanaga, K., Fujisue, K., Hoshiyama, T., Kanazawa, H., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.10.015 · Cited by 16
Safety of temporary interruption of antiplatelet therapy in dengue fever with thrombocytopenia
Chia, P. Y., Htun, H. L., Leo, Y., & Lye, D. C. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.10.038 · Cited by 13
Lim, S., Choo, E. H., Choi, I. J., Lee, K. Y., Lee, S. N., Hwang, B., Kim, C. J., Park, M., Lee, J. M., Park, C. S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163642 · Cited by 13
Doomun, D., Doomun, I., Schukraft, S., Arroyo, D., Cook, S. T., Huwyler, T., Wenaweser, P., Stauffer, J., Goy, J., Togni, M., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.620354 · Cited by 13
“The main results of this study are: (1) patients defined as HBR by the ARC-HBR definition are frequent in an unselected European population undergoing PCI; (2) the criteria defined by ARCHBR accurately predict bleeding risk; (3) the impact of HBR risk factors is incremental; (4) one-third of major bleeding occurs duri…”
BackgroundResultOptimal cardiovascular medical therapy: current guidelines and new developments
Reed, S., Dhir, N., & Widmer, R. J. (2022) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2022.2083903 · Cited by 15
“Longer duration was also associated with a higher incidence of bleeding and all-cause mortality.(10) All told, for 1000 patients continued on DAPT therapy, three cases of stent thromboses and six MIs would be avoided at the cost of five major bleeds with an increase in noncardiac mortality.”
BackgroundPopa, P., Iordache, S., Florescu, D. N., Iovănescu, V. F., Vieru, A.-M., Barbu, V., Beznă, M. C., Alexandru, D. O., Ungureanu, B. S., & Cazacu, S. M. (2022) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s380500 · Cited by 13
Lansky, A. J., Xu, B., Baumbach, A., Kelbæk, H., van Royen, N., Zheng, M., Knaapen, P., Slagboom, T., Johnson, T., Vlachojannis, G. J., et al. (2023) · EuroIntervention · doi:10.4244/eij-d-23-00409 · Cited by 13
Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models
Palekar, R. U., Vemuri, C., Marsh, J. N., Arif, B., & Wickline, S. A. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.08.086 · Cited by 13
“In fact, recent reports from the Dual Antiplatelet Therapy (DAPT) study have demonstrated that the current standard of dual antiplatelet therapy (P2Y12-receptor inhibitor plus aspirin) for prevention of thrombotic complications after placement of drugeluting stents may require extended use beyond 1 year after stenting…”
BackgroundShah, R. R., Pillai, A., Omar, A., Zhao, J. Z., Arora, V., Kapoor, D., & Poommipanit, P. B. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26588 · Cited by 13
“Conversely, continued thienopyridine therapy beyond the initial 12 months was likewise associated with an increased risk of moderate or severe bleeding [2].”
BackgroundGliesche, D. G., Hußner, J., Witzigmann, D., Porta, F., Glatter, T., Schmidt, A., Huwyler, J., & zu Schwabedissen, H. E. M. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00033 · Cited by 13
Dual antiplatelet therapy after coronary stenting
Park, Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1202924 · Cited by 13
“Importantly, the ischemic benefits of prolonged DAPT may not be confined to the stented segments, as better described below [35,36].”
BackgroundInfluentialIm, E., Cho, Y., Suh, Y., Cho, D., Her, A., Kim, Y. H., Lee, K., Kang, W. C., Yun, K. H., Yoo, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.06.008 · Cited by 13
Hernández, J. M. D. L. T., & Edelman, E. R. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.07.017 · Cited by 13
Lam, D. H., Bell, S. M., & Hira, R. S. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0703-4 · Cited by 13
Raposeiras‐Roubín, S., Queija, B. C., D’Ascenzo, F., Kinnaird, T. D., Ariza‐Solé, A., Manzano‐Fernández, S., Templin, C., Velicki, L., Xanthopoulou, I., Cerrato, E., et al. (2018) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2018.06.004 · Cited by 13
Metadata
- Authors
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Krucoff, M. W., Hermiller, J., Dauerman, H. L., Simon, D. I., Kandzari, D. E., Garratt, K. N., Lee, D. P., Pow, T. K., Ver Lee, P., Rinaldi, M. J., & Massaro, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Christ Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Missouri–Kansas City (US)
- Duke Medical Center (US)
- St Vincent Hospital (US)
- University of Vermont (US)
- University Hospitals Cleveland Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Lenox Hill Hospital (US)
- Stanford University (US)
- Carolinas Healthcare System (US)
- Boston University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2155-2166
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481318
- OpenAlex
- W2125173296
- Cited by
- 1,928
- References
- 39
- Citations by year
- 2026: 69 · 2025: 75 · 2024: 80 · 2023: 109 · 2022: 125 · 2021: 154 · 2020: 182 · 2019: 150 · 2018: 183 · 2017: 242 · 2016: 288 · 2015: 254 · 2014: 9
- FWCI
- 181.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Food and Drug Administration (1r01fd003870-01, R01 FD003870)
- National Heart, Lung, and Blood Institute (R01HL057506, R37HL057506, K23HL118138)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, drug-eluting stents, coronary stenting, clopidogrel, prasugrel, thienopyridines, aspirin, stent thrombosis, major adverse cardiovascular events, bleeding risk, myocardial infarction, stroke, mortality, periprocedural bleeding, bleeding risk stratification
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Thrombosis, Ticlopidine, Time Factors, Incidence, Myocardial Ischemia, Drug-Eluting Stents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.